MDCX
Medicus Pharma Ltd. Common StockMDCX
MDCX
About: Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Employees: 12
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
12.72% more ownership
Funds ownership: 0% [Q3] → 12.72% (+12.72%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
233%
upside
Avg. target
$14
233%
upside
High target
$14
233%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 233%upside $14 | Buy Maintained | 28 Apr 2025 |
Financial journalist opinion
Based on 4 articles about MDCX published over the past 30 days
Positive
Proactive Investors
2 days ago
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer. Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.
Neutral
Newsfile Corp
2 days ago
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate Cancer Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd.
Positive
Proactive Investors
1 week ago
Medicus Pharma expands basal cell carcinoma study after encouraging early data
Medicus Pharma (NASDAQ:MDCX) said it has received approval from an Institutional Review Board (IRB) to increase the number of participants in its ongoing Phase 2 clinical trial of a novel non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The company will raise the trial's enrollment target to 90 patients from 60 and expand the study beyond the current nine clinical sites in the United States to additional US locations and two in Europe.
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd.
Neutral
Newsfile Corp
1 month ago
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit.
Positive
Proactive Investors
1 month ago
Medicus Pharma CEO discusses latest skin cancer trial results - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest progress in the company's ongoing clinical trials for its innovative skin cancer treatment. The company is developing a non-invasive microneedle-based therapy designed to treat basal cell carcinoma by delivering doxorubicin directly to the lesion site.
Neutral
Proactive Investors
1 month ago
Medicus Pharma unveils pricing of financing to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its Tier II Regulation A offering, aiming to raise approximately $4.2 million through the sale of 1.49 million units at $2.80 per unit. Each unit includes one common share and one warrant, with the warrants exercisable at $2.80 per share for a five-year period.
Neutral
Newsfile Corp
1 month ago
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit.
Positive
Proactive Investors
1 month ago
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
Neutral
Newsfile Corp
1 month ago
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
Charts implemented using Lightweight Charts™